Toshiaki Takagi - Terumo Senior Executive Officer, Director
| TRUMF Stock | USD 19.60 1.27 6.09% |
Director
Mr. Toshiaki Takagi was serving as Senior Managing Executive Officer, Chief Quality Officer and Director in Terumo Corporation since April 2018. He joined the Company in April 1981. His previous titles include Ashitaka Plant Manager, Managing Executive Officer, Senior Executive Officer and Executive Officer in the Company. since 2018.
| Age | 65 |
| Tenure | 6 years |
| Phone | 81 3 3374 8111 |
| Web | https://www.terumo.co.jp |
Terumo Management Efficiency
The company has return on total asset (ROA) of 0.0441 % which means that it generated a profit of $0.0441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0763 %, meaning that it generated $0.0763 on every $100 dollars invested by stockholders. Terumo's management efficiency ratios could be used to measure how well Terumo manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paul Saillant | EssilorLuxottica Socit anonyme | 64 | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| Harjit Gill | ResMed Inc | 55 | |
| Colleen Jay | The Cooper Companies, | 58 | |
| Douglas Michels | West Pharmaceutical Services | 63 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| Paula Johnson | West Pharmaceutical Services | 59 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
| Richard Sulpizio | ResMed Inc | 70 | |
| Claire Pomeroy | Becton Dickinson and | 65 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| Paul Saillant | Essilor International SA | 64 | |
| Jeffrey Henderson | Becton Dickinson and | 56 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Kim Duncan | The Cooper Companies, | N/A | |
| Timothy Ring | Becton Dickinson and | 63 | |
| Deborah Tanner | West Pharmaceutical Services | 57 | |
| Carol Burt | ResMed Inc | 62 | |
| William Feehery | West Pharmaceutical Services | 50 | |
| David Melcher | Becton Dickinson and | 66 | |
Management Performance
| Return On Equity | 0.0763 | |||
| Return On Asset | 0.0441 |
Terumo Leadership Team
Elected by the shareholders, the Terumo's board of directors comprises two types of representatives: Terumo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Terumo. The board's role is to monitor Terumo's management team and ensure that shareholders' interests are well served. Terumo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Terumo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Toshiaki Takagi, Senior Executive Officer, Director | ||
| Kazunori Hirose, Executive Officer, Vice President of Base Medical Device Business Operation Unit in Hospital Company | ||
| Shoji Hatano, Senior Executive Officer, Manager of Business Planning Office | ||
| Hikaru Samejima, Executive Officer and Presidentident of Interventional Systems Business in Cardiovascular Company | ||
| Naoki Muto, Chief Officer | ||
| Miho Mizuguchi, Executive Officer, Chief Legal Officer, Manager of Legal & Compliance Office | ||
| Fumihisa Hirose, Executive Officer, Senior Vice President of Cardiovascular Company | ||
| Tsuyoshi Tomita, Senior Executive Officer, Vice President of Hospital Company, Manager of Earnings Recovery Office in Hospital Company and Presidentident of DM & Health Care Business in Hospital Company | ||
| Shinjiro Sato, Senior Executive Officer, Director | ||
| Kyo Nishikawa, Executive Officer and Presidentident of Subsidiary |
Terumo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Terumo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0763 | |||
| Return On Asset | 0.0441 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 21.89 B | |||
| Shares Outstanding | 734.2 M | |||
| Shares Owned By Insiders | 4.32 % | |||
| Shares Owned By Institutions | 57.19 % | |||
| Price To Earning | 31.69 X | |||
| Price To Book | 2.51 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Terumo Pink Sheet
Terumo financial ratios help investors to determine whether Terumo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Terumo with respect to the benefits of owning Terumo security.